Press and Media

Home / Meetings / Press and Media
Thank you for your coverage of the AANEM Annual Meeting. Please join us at the 2025 AANEM Annual Meeting, being held Oct.29-Nov. 1 in San Francisco, California. Journalists covering the annual meeting and posting stories on social media channels are encouraged to use the official meeting hashtag #AANEMinSanFran.
Please review the Abstract Embargo Policy. For questions regarding AANEM Annual Meeting policies, please email communications@aanem.org.

View the latest AANEM Achievement Award winners, the American Neuromuscular Foundation (ANF) Abstract Award winners, and the latest AANEM news articles on News Express.

Questions? Check out the frequently asked questions below or contact communications@aanem.org. 

Frequently Asked Questions

Q: When will be content of abstracts be viewable, as opposed to just the titles?
A: The abstract content will be available at the annual meeting during the Poster Hall hours. We do not provide abstract presenter information or slides ahead of time. All available information can be found in the AANEM Abstract Guide online when it becomes available.

Q: How do I reach out to abstract or session presenters for an interview?
A: We do not offer member contact information. To connect with abstract or session presenters, review the AANEM Annual Meeting Program when available. Find the topics of interest and connect with the presenter after their lecture or during their abstract poster session time. Currently there is no interview option for virtual attendees.

Q: When can I share information?
A: The embargo on the abstracts themselves is lifted when they have been published in Muscle & Nerve and online in the AANEM Abstract Guide. However, the additional information beyond what is in the abstract itself is still embargoed. 

AANEM requires information that goes beyond that which is contained within the abstract, e.g., the release of data not included in the abstract, discussion of the abstract done as part of a scientific presentation, etc. to be embargoed until the start of the annual meeting. Please see the Abstract Embargo Policy.

Q: Will the Abstract Award Reception feature the best posters? 
A: The Abstract Award Reception is a social hour in honor of the abstract award winners where all authors, including award winners, will be available to discuss research. 

Q: Original research is ONLY presented as posters, correct?
A: Yes - the research is presented in the Poster Hall via abstract posters.

Science News: GLP-1RA–Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies A Case-Control Evaluation

Jan 8, 2026, 11:33 by DeeDee Stiepan
Diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN) are associated with weight loss. The authors examined whether GLP-1RA usage is linked to these neuropathies.

Submitted by: Justin Aaron Willer MD, FAAN
Edited by: Rebecca O'Bryan, MD
Citation: Triplett JD, Pinto MV, Young NP, et al. GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation. Neurology. 2025;105(3):e213916. doi:10.1212/WNL.0000000000213916

Summary: Diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN) are associated with weight loss. The authors examined whether GLP-1RA usage is linked to these neuropathies.

26 patients had 27 episodes of DLRPN. Median onset was 6 months after initiation of treatment. Average HbA1c reduction was 2.4%, and there was an average of 13.9% weight loss. Microvasculitis was present in 4 of 5 nerve biopsies.

77 patients with CFN had 82 episodes of CFN with mean duration of treatment with GLP-1 of 15 months and median reduction in HbA1c of 1.2% with an average of 15% weight loss. The deep fibular branches were more affected than the superficial fibular nerve branches. A CMAP reduction of more than 30% was noted in 58 cases, a reduction of more than 50% in 46 cases, and an absent response in 21 cases.

One patient with DLRPN had previously had gastric bypass surgery 5 years earlier without developing DLRPN prior to GLP-1 usage.

Six patients with CFN had previous or distant history of gastric bypass surgery without prior history of CFN.

Patients with DLRPN compared to CFN had greater HbA1c reduction (2.4% vs 1.2%). Non-arteritic ischemic optic neuropathy, macular edema and retinopathy was not observed in this cohort.

Compared to controls, patients receiving GLP-1 were 51% more likely to experience DLRPN and 305 more likely to experience CFN.

Patients had poor glycemic control and obesity but minimal prior microvascular complications.

DLRPN is noted to have overlapping features with treatment induced neuropathy (TIND). 

Comments: This study indicates a need for closer monitoring of weight shifts and HbA1c in patients on GLP-1 and if rapid drops are found then reducing the dose of the GLP-1 or switching to an alternate medication should be considered.

GLP-1RAs are proposed to contribute to the development of DLRPN through metabolic shifts and rapid HbA1c reduction while CFN appears to be more related to weight loss.

Consider DLRPN in patients with marked decrease in HbA1c and new onset pain and consider the presence of fibular neuropathy at the fibular head in patients with significant weight loss on GLP-1.